Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amrubicin (alone or with cisplatin) versus etoposide + cisplatin as first-line therapy in extensive-stage small cell lung cancer
2006-001956-11Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of amrubicin in small cell lung cancer (SCLC) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Overall response rate. Started Jul 2006; status: completed.
02
Drugs
amrubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2006-001956-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001956-11.